San Diego, California
Professor of Surgery and Epidemiology
University of California San Diego, Johns Hopkins Bloomberg School of Public Health
Chief Vascular and Endovascular Surgery
University of California San Diego
SCHEDULE FOR VEITHsymposium™
Wednesday, November 17, 2021
Presenter
SESSION 43: MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; LINK TO CANCER; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAS ARE NOT TIME BOMBS WAITING TO EXPLODE
DEBATE: Not So: Ovation Stent-Graft (From Endologix) Have Good 5-Year Results With No Neck Dilatation Or Migration Even With Challenging Neck Anatomy: Based On A Multicenter International Study Of A Low Profile Endograft
1:36 PM - 1:41 PM
Friday, November 19, 2021
Presenter
SESSION 80: NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS WITH MESH COVERED STENTS AND TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION (TCAR)
TCAR Versus CEA (Carotid Endarterectomy): A Propensity Matched SVS VQI Study: 1-Year Results Show Equal Stroke/Death Rates And Decreased Cranial Nerve Injuries With TCAR: Findings Also Confirmed By A Meta-Analysis
8:17 AM - 8:22 AM
Presenter
SESSION 82: MORE CAROTID RELATED NEW DEVELOPMENT TOPICS RELATED TO TCAR, MESH COVERED STENTS, MINI-INCISION CEA, TIMING OF TREATMENT, MEDICAL TREATMENT AND DEALING WITH DISTAL (HIGH) CAROTID LESIONS
Optimal Timing Of Carotid Revascularization (CEA, TFCAS, TCAR) After Symptom Onset: Within 48 Hours Risk Is Increased For All Procedures; After 48 Hours Risk Is Less With CEA And TCAR Than With TFCAS: Based On Large National Database Study
11:12 AM - 11:17 AM
Saturday, November 20, 2021
Presenter
SESSION 106: AORTIC AND CAROTID TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)
TCAR With Flow Reversal Versus Transcervical CAS With Distal Protection: TCAR’s Benefit Is Not Just Due To Its Avoidance Of Having To Traverse The Aortic Arch
12:20 PM - 12:25 PM
 
previous next